Generated by AI
LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.
Website201 Lomas Santa Fe Drive
Solana Beach, CA, 92075
United States
The latest articles about LENZ.
LENZ Therapeutics faces mounting cash burn, imminent dilution risk, and severe operational cuts, with no R&D pipeline. I rate LENZ stock as Sell. Read my analysis.
Summary of Oct 29's posts. Generated by AI.
No summary yet.
Summary of Mar 15's posts. Generated by AI.
No summary yet.
Summary of Oct 29's posts. Generated by AI.
Investors talking about LENZ also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.